Arthrex Ordered to Stop Selling Infringing Products

             Arthrex Ordered to Stop Selling Infringing Products

PR Newswire

ANDOVER, Mass., Oct. 3, 2013

ANDOVER, Mass., Oct. 3, 2013 /PRNewswire/ -- Smith & Nephew (LSE: SN, NYSE:
SNN), the global medical technology business, announces that the U.S. District
Court in Oregon issued significant rulings in its favor in the patent
infringement case (U.S. Patent 5,601,557) with Arthrex, Inc. (Naples, Fla.).

As part of the ruling the Court has ordered Arthrex to stop selling its
Bio-SutureTak and PEEK SutureTak products in the U.S. as of yesterday, October
2, 2013.

The patent covers technology used in certain Smith & Nephew anchors (such as
BIORAPTOR™ Suture Anchors, FOOTPRINT™ Ultra PK, and OSTEORAPTOR™) used
primarily in surgical repair of the shoulder. In June 2011, a jury found that
Arthrex's Bio-SutureTak, PEEK SutureTak, and certain Bio-PushLock and PEEK
PushLock suture anchors infringe the patent owned by Dr. John O. Hayhurst
(Portland, Ore.) and under exclusive license to Smith & Nephew.

"Smith & Nephew is dedicated to providing innovative healthcare products and
services to our surgeon customers and their patients, and we will vigorously
defend our intellectual property when warranted," commented Mike Frazzette,
President, Advanced Surgical Devices Division, Smith & Nephew.

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping
improve people's lives. With leadership positions in Orthopaedic
Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith &
Nephew has around 11,000 employees and a presence in more than 90 countries.
Annual sales in 2012 were more than $4.1 billion. Smith & Nephew is a member
of the FTSE100 (LSE: SN, NYSE: SNN).

For more information about Smith & Nephew, please visit: www.smith-nephew.com

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth and
trading margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate",
"well-placed", "believe", "estimate", "expect", "target", "consider" and
similar expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual results to
differ materially from what is expressed or implied by the statements. For
Smith & Nephew, these factors include: economic and financial conditions in
the markets we serve, especially those affecting health care providers, payors
and customers; price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals, reimbursement
decisions or other government actions; product defects or recalls; litigation
relating to patent or other claims; legal compliance risks and related
investigative, remedial or enforcement actions; strategic actions, including
acquisitions and dispositions, our success in integrating acquired businesses,
and disruption that may result from changes we make in our business plans or
organisation to adapt to market developments; and numerous other matters that
affect us or our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission under the
U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's
most recent annual report on Form 20-F, for a discussion of certain of these
factors.

Any forward-looking statement is based on information available to Smith &
Nephew as of the date of the statement. All written or oral forward-looking
statements attributable to Smith & Nephew are qualified by this caution. Smith
& Nephew does not undertake any obligation to update or revise any
forward-looking statement to reflect any change in circumstances or in Smith &
Nephew's expectations.

Trademark of Smith & Nephew. Registered US Patent and Trademark Office.



Enquiries
               +1 (978) 749-1330
Media
               joe.metzger@smith-nephew.com
Joe Metzger

Smith & Nephew
Investors
               +44 (0)20 7401 7646
Phil Cowdy
               
Smith & Nephew

SOURCE Smith & Nephew

Website: http://www.smith-nephew.com
 
Press spacebar to pause and continue. Press esc to stop.